Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both multiple myeloma and refractory advanced colorectal cancer, and in Phase 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing ZerenexTM (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of ZerenexTM in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx also actively engages in business development activities that include seeking strategic relationships for its product candidates, as well as evaluating compounds and companies for in-licensing or acquisition.
Keryx is headquartered in New York City.
Keryx Biopharmaceuticals is traded on the Nasdaq Stock Market under the symbol "KERX."
Corporate Headquarters
Keryx Biopharmaceuticals, Inc.
750 Lexington Ave. - 20th Floor
New York, NY 10022
Phone: 1-212-531-5965
Fax: 1-212-531-5961
| Product candidate | Target indication | Development status |
| | | |
| ZerenexTM (ferric citrate) | Hyperphosphatemia in patients with end-stage renal disease | U.S. Phase 3 program ongoing under SPA;
Japan Phase 3 program ongoing by sublicensee (JT and Torii) |
Recent News: http://ih.advfn.com/p.php?pid=news&symbol=N%5EKERX http://www.otcmarkets.com/stock/KERX/news http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-news&nyo=0
Charts:
Gallery views:
http://stockcharts.com/freecharts/gallery.html?kerx
KERX - Daily Candlesticks
Analyst's estimates and ratings:
http://investing.money.msn.com/investments/analyst-ratings/?symbol=kerx
http://www.marketwatch.com/investing/stock/KERX/analystestimates?subview=snapshot&pg=analyst
The most recent Quarterly (10-Q)